Integrating Chinese herbal medicine in advanced lung cancer: A multicenter real-world study using target trial emulation
Phytomedicine · 2025
DOI: 10.1016/j.phymed.2025.157239 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Phytomedicine, 2025. Verfasst von Ting-Tzu Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chinese Gynecology, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Lung Neoplasms, Drugs, Chinese Herbal, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital, Ministry of Health and Welfare.
Abstract (Originalsprache)
BACKGROUND: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, particularly in advanced stages. While Chinese herbal medicine (CHM) is often used as part of integrative treatment, its long-term impacts on stage IV NSCLC are not fully elucidated. METHODS: This retrospective cohort study used a multi-institutional dataset from the Chang Gung Research Database with a target trial emulation design. Patients newly diagnosed with stage IV NSCLC between January 1, 2011, and December 31, 2021, were enrolled and followed for up to 10 years. Overall survival (OS) and cancer-specific survival (CSS) were estimated using Kaplan-Meier analysis with overlap weighting. Core CHMs and their biomedical pathways were explored through network pharmacology analysis. RESULTS: A total of 6395 patients were analyzed, with approximately 18.1 % using CHM during treatment. Integrative CHM use was associated with more favorable outcomes, with higher 10-year OS rates (8.2 % vs. 3.4 % with overlap weighting; p-value < 0.001) and CSS rates (11.5 % vs. 4.4 % with overlap weighting; p-value < 0.001). Integrative CHM use with EGFR-TKI linked to the highest 10-year OS rate at 9.6 %. Core CHMs, including Hedyotis diffusa Willd., Morus alba l., QZJFT, Kochia scoparia (l.) Schrad. with Sophora flavescens Ait., were associated with reduced mortality risk, targeting metabolic and immune pathways. CONCLUSION: As the first study applying target trial emulation and network pharmacology analysis on real-world databases, this study highlights that integrative CHM, particularly alongside EGFR-TKI therapy, may have better outcomes in stage IV NSCLC patients, providing critical insights for clinical application and research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chinese Gynecology, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
- Division of Haematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Division of Hematology-Oncology, Department of Internal Medicine, New Taipei Municipal Tucheng…
- Division of Chinese Acupuncture and Traumatology, Center of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan; School of Traditional Chinese Medicine, College of Medicine, Chang Gung University…
- School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyua…
Förderung
- Chang Gung Medical Foundation
- Linkou Chang Gung Memorial Hospital
- Ministry of Health and Welfare
- National Science and Technology Council
Zitieren
APA
Lu, T. T., Wu, C. E., Huang, T. H., Chen, J. L., Yang, C. W., & Chen, H. Y. (2025). Integrating Chinese herbal medicine in advanced lung cancer: A multicenter real-world study using target trial emulation. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157239
Vancouver
Lu TT, Wu CE, Huang TH, Chen JL, Yang CW, Chen HY. Integrating Chinese herbal medicine in advanced lung cancer: A multicenter real-world study using target trial emulation. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157239
BibTeX
@article{Lu2025,
author = {Lu, Ting-Tzu and Wu, Chiao-En and Huang, Tse-Hung and Chen, Jiun-Liang and Yang, Ching-Wei and Chen, Hsing-Yu},
title = {Integrating Chinese herbal medicine in advanced lung cancer: A multicenter real-world study using target trial emulation},
journal = {Phytomedicine},
year = {2025},
doi = {10.1016/j.phymed.2025.157239}
}
EUVIMED